Pharmaceutical News

RSS

CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

Several Cancer Treatment Centers of America clinicians presented research from studies evaluating new cancer nutrition techniques and therapies at the American Society for Parenteral and Enteral Nutrition Clinical Nutrition Week held in Long Beach, Calif., February 14-17, 2015. CTCA clinicians led a plenary session and an oral abstract presentation, and presented eight posters to Clinical Nutrition Week attendees.

18 Feb 2015

Nicotine addiction medication produces greater reductions in smoking prior to quitting

Among cigarette smokers not willing or able to quit smoking in the next month but willing to reduce with the goal of quitting in the next 3 months, use of the nicotine addiction medication varenicline for 24 weeks compared with placebo produced greater reductions in smoking prior to quitting and increased smoking cessation rates at the end of treatment and at 1 year, according to a study in the February 17 issue of JAMA.

18 Feb 2015

Corticosteroids decrease treatment failure among patients with community-acquired pneumonia

Among patients with severe community-acquired pneumonia and high initial inflammatory response, the use of the corticosteroid methylprednisolone decreased treatment failure, compared with placebo, according to a study in the February 17 issue of JAMA.

18 Feb 2015

Rivers, streams could be a major source of antibiotic resistance in the environment

Rivers and streams could be a major source of antibiotic resistance in the environment. The discovery comes following a study on the Thames river by scientists at the University of Warwick's School of Life Sciences and the University of Exeter Medical School.

17 Feb 2015

Cabazitaxel therapy may be more effective in treating prostate cancer

Prostate cancer is the second leading cause of cancer for men in the United States. Only one class of chemotherapy called taxanes is effective against the disease.

17 Feb 2015

Oncolytics Biotech’s REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.

17 Feb 2015

Celon, Lupin sign definitive agreement to develop generic version of Advair Diskus

Pharma Major Lupin Limited (Lupin) and Celon Pharma S.A. (Celon) announced today that they have entered into a definitive agreement under which the companies will jointly develop a fluticasone/salmeterol dry powder inhaler (DPI) product which is a generic version of GlaxoSmithKline's Advair Diskus®.

17 Feb 2015

BGRF announces publication of research into personalising nootropic drugs using in silico prediction methods

The Biogerontology Research Foundation (BGRF), a UK-based charity committed to the support of aging research to address the challenges of a rapidly aging population and to reduce the impact of disease on future generations, announces the publication of research into personalising nootropic drugs using in silico prediction methods.

17 Feb 2015

Experts provide suggestions to prevent neurological injuries associated with epidural steroid injections

Epidural steroid injections are commonly used to treat pain; however, they can in rare situations produce life-threatening neurological injuries such as stroke and paralysis. In the Online First edition of February's Anesthesiology, the official medical journal of the American Society of Anesthesiologists, a panel of experts representing 13 national medical organizations provided 17 suggestions aimed at preventing such injuries and improving patient safety.

16 Feb 2015

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets.

16 Feb 2015

AARDA releases white paper to educate its members, patient community about biosimilar medicines

The American Autoimmune Related Diseases Association, a national nonprofit health organization dedicated to increasing awareness of autoimmune diseases, today issued a white paper to educate its membership and the patient community about biosimilar medicines after a survey found most patients were generally unaware of this new category of medicines which may soon be approved in the U.S.

16 Feb 2015

Increasing opioid doses to manage chronic pain may intensify depression

Patients who increased doses of opioid medicines to manage chronic pain were more likely to experience an increase in depression, according to Saint Louis University findings in Pain.

16 Feb 2015

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis announced today that the US Food and Drug Administration has granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation is intended to accelerate the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition.

16 Feb 2015

Experts discuss therapeutic potential of medical cannabis in a symposium organized by MUHC

While debate about recreational marijuana use continues, researchers are investigating the effectiveness of cannabis for treating pain, spasticity, and a host of other medical problems. In a symposium organized by the McGill University Health Centre as part of the 2015 American Association for the Advancement of Science Annual Meeting held this week in San Jose, California, world-renowned experts from North America and the U.K. share their perspectives on the therapeutic potential of medical cannabis and explore the emerging science behind it.

16 Feb 2015

Cervarix effective against other common cancer-causing HPVs

According to a multinational clinical trial involving nearly 20,000 young women, the human papilloma virus vaccine, Cervarix, not only has the potential to prevent cervical cancer, but was effective against other common cancer-causing human papillomaviruses, aside from just the two HPV types, 16 and 18, which are responsible for about 70 percent of all cases.

15 Feb 2015

New antibody shows promise in increasing survival for patients suffering from influenza, pneumonia

Scientists from NTU Singapore, the world's No. 1 young university, have developed an antibody which boosts the survival chances for patients suffering from influenza and pneumonia.

14 Feb 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

Actavis releases generic version of Pulmicort RESPULES

Actavis plc today announced that it has launched its generic version of AstraZeneca's Pulmicort RESPULES® (budesonide inhalation suspension) 0.25 and 0.5 mg vials following a ruling from the United States District Court for the District of New Jersey that (i) United States Patent No. 7,524,834 is invalid, and (ii) AstraZeneca's request for a permanent injunction is denied.

13 Feb 2015

Adolescents meth abusers suffer greater alterations in their brain than adult drug abusers

Adolescents who chronically use methamphetamine suffer greater and more widespread alterations in their brain than adults who chronically abuse the drug-and damage is particularly evident in a part of the brain believed to control the "executive function," researchers from the University of Utah and South Korea report.

13 Feb 2015

Health Canada to review Cipher’s self-adhesive medicated plaster, Beteflam Patch

Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Beteflam Patch (previously called the Betesil® Patch) has been accepted for review by Health Canada.

13 Feb 2015

Pharmaceutical News

CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

Nicotine addiction medication produces greater reductions in smoking prior to quitting

Corticosteroids decrease treatment failure among patients with community-acquired pneumonia

Rivers, streams could be a major source of antibiotic resistance in the environment

Cabazitaxel therapy may be more effective in treating prostate cancer

Oncolytics Biotech’s REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

Celon, Lupin sign definitive agreement to develop generic version of Advair Diskus

BGRF announces publication of research into personalising nootropic drugs using in silico prediction methods

Experts provide suggestions to prevent neurological injuries associated with epidural steroid injections

Hospira announces launch of first biosimilar monoclonal antibody in Europe

AARDA releases white paper to educate its members, patient community about biosimilar medicines

Increasing opioid doses to manage chronic pain may intensify depression

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Experts discuss therapeutic potential of medical cannabis in a symposium organized by MUHC

Cervarix effective against other common cancer-causing HPVs

New antibody shows promise in increasing survival for patients suffering from influenza, pneumonia

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Actavis releases generic version of Pulmicort RESPULES

Adolescents meth abusers suffer greater alterations in their brain than adult drug abusers

Health Canada to review Cipher’s self-adhesive medicated plaster, Beteflam Patch

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News